Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials.

导出 LinkOut

翻译打印收藏纠错

第一作者： Kusha A,Mohammadi

第一单位： Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.

作者： Kusha A,Mohammadi ^[1] ; Taylor,Brackin ^[1] ; Gregory G,Schwartz ^[2] ; Philippe Gabriel,Steg ^[3] ; Michael,Szarek ^[4] ; Garen,Manvelian ^[5] ; Robert,Pordy ^[6] ; Sergio,Fazio ^[7] ; Gregory P,Geba ^[1]

作者单位： Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA. ^[1] University of Colorado School of Medicine, Aurora, Colorado, USA. ^[2] Université Paris-Cité, Paris, France. ^[3] FACT (French Alliance for Cardiovascular Trials) INSERM U1148, Paris, France. ^[4] Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France. ^[5] State University of New York, Downstate School of Public Health, Brooklyn, New York, USA. ^[6] CPC Clinical Research and Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA. ^[7]

关键词 LDL-C PCSK9 inhibitor alirocumab cholesterol incident cancer serum lipids

主题词人类(Humans);抗体, 单克隆(Antibodies, Monoclonal);胆固醇, LDL(Cholesterol, LDL);羟甲基戊二酰基CoA还原酶抑制剂(Hydroxymethylglutaryl-CoA Reductase Inhibitors);肿瘤(Neoplasms);危险性评估(Risk Assessment);枯草杆菌蛋白酶类(Subtilisins);治疗结果(Treatment Outcome)

DOI 10.1002/cam4.6310

PMID 37458138

发布时间 2023-09-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancer medicine

2023年12卷16期

16859-16868页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials.

Cancer medicine

相似文献

Cancer medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials.

Cancer medicine

相似文献

Cancer medicine

相关期刊

检索历史清除